11 completed, 8 terminated, 2 active not recruiting, 1 withdrawn. 15 Phase 2, 13 Phase 1.
| Phase | Trials | Status |
|---|---|---|
| Phase 2 | 15 | Completed 8, Terminated 7 |
| Phase 1 | 13 | Completed 7, Terminated 3, Active not recruiting 2, Withdrawn 1 |
Follow mocetinostat: new trials by email Literature Review of mocetinostat trials Research Report on mocetinostat
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Mocetinostat With Vinorelbine in Children, Adolescents & Young Adults With Refractory and/or Recurrent Rhabdomyosarcoma Vinorelbine, Mocetinostat - Rhabdomyosarcoma | Phase 1 | Active not recruiting | Jonsson Comprehensive Cancer Center | 14 | 2020-05-14 | 2026-07-17 |
| Pre-operative Mocetinostat (MGCD0103) and Durvalumab (MEDI4736) (PRIMED) for Squamous Cell Carcinoma of the Oral Cavity Mocetinostat, Durvalumab - Squamous Cell Carcinoma, Head And Neck, Squamous Cell Carcinoma Mouth | Phase 1 | Withdrawn | University Health Network, Toronto | 2017-10-10 | 2017-12-29 | |
| Pembrolizumab (Immunotherapy Drug) in Combination With Guadecitabine and Mocetinostat (Epigenetic Drugs) for Patients With Advanced Lung Cancer. Pembrolizumab, Guadecitabine, Mocetinostat - Lung Cancer | Phase 1 | Active not recruiting | Memorial Sloan Kettering Cancer Center | 28 | 2017-08-04 | 2026-08-05 |
| Phase 2 Study of Glesatinib, Sitravatinib or Mocetinostat in Combination With Nivolumab in Non-Small Cell Lung Cancer Glesatinib, Sitravatinib, Mocetinostat - Carcinoma, Non-Small-Cell Lung | Phase 2 | Terminated | Mirati Therapeutics Inc. | 161 | 2016-11-07 | 2024-04-22 |
| Phase 1/2 Study of Mocetinostat and Durvalumab in Patients With Advanced Solid Tumors and NSCLC Mocetinostat - 50 mg, Mocetinostat - 70 mg, Mocetinostat - 90 mg - Advanced Cancer | Phase 1 / Phase 2 | Terminated | Mirati Therapeutics Inc. | 83 | 2016-06-01 | 2021-04-06 |
| SARC018: A Study of Mocetinostat and Gemcitabine in Patients With Metastatic Leiomyosarcoma Mocetinostat, Gemcitabine - Metastatic Leiomyosarcoma | Phase 2 | Completed | Sarcoma Alliance for Research through Collaboration | 20 | 2015-11-12 | 2019-01-29 |
| Mocetinostat (MGCD0103) Plus Brentuximab Vedotin (SGN-35) in Patients With Relapsed or Refractory Hodgkin Lymphoma Mocetinostat Plus Brentuximab Vedotin - Hodgkin Lymphoma | Phase 1 / Phase 2 | Completed | Memorial Sloan Kettering Cancer Center | 7 | 2015-04-22 | 2022-05-12 |
| Study of Mocetinostat in Selected Patients With Mutations of Acetyltransferase Genes in Relapsed and Refractory Diffuse Large B-Cell Lymphoma and Follicular Lymphoma Mocetinostat - Lymphoma, Relapsed and Refractory | Phase 1 / Phase 2 | Terminated | Memorial Sloan Kettering Cancer Center | 7 | 2014-10-01 | 2024-03-08 |
| Study of Mocetinostat in Patients With Urothelial Carcinoma Having Inactivating Alterations of Specific Genes Mocetinostat - Urothelial Carcinoma | Phase 2 | Completed | Mirati Therapeutics Inc. | 17 | 2014-10-01 | 2017-09-01 |
| Safety Study of Mocetinostat in Combination With Azacitidine in Subjects With MDS Mocetinostat, Azacitidine - Myelodysplastic Syndrome | Phase 1 / Phase 2 | Completed | Mirati Therapeutics Inc. | 18 | 2013-12-01 | 2017-09-14 |
| Phase 2 Study of Azacitidine (Vidaza) vs MGCD0103 vs Combination in Elderly Subjects With Newly Diagnosed Acute Myeloid Leukemia (AML) or Myelodysplastic Syndrome (MDS) Azacitidine, MGCD0103 - Acute Myeloid Leukemia (AML), Myelodysplastic Syndrome (MDS) | Phase 2 | Terminated | Mirati Therapeutics Inc. | 6 | 2008-06-01 | 2015-05-08 |
| MGCD0103 Administered in Combination With Azacitidine (Vidaza®) to Subjects With Relapsed or Refractory Hodgkin or Non-Hodgkin Lymphoma MGCD0103 and Azacitidine - Hodgkin Lymphoma, Non-Hodgkin Lymphoma (Follicular or Large Diffuse B-cell Lymphoma or Mantle Cell Lymphoma) | Phase 2 | Terminated | Mirati Therapeutics Inc. | 23 | 2007-10-01 | 2015-07-01 |
| Study to Evaluate Combination Treatment of MGCD0103 and Docetaxel (Taxotere®) for Subjects With Advanced Cancer Tumors MGCD0103 & Docetaxel - Breast Cancer, Lung Cancer | Phase 1 | Terminated | Mirati Therapeutics Inc. | 54 | 2007-08-01 | 2015-01-08 |
| A Phase II Study of MGCD0103 (MG-0103) in Patients With Refractory Chronic Lymphocytic Leukemia MGCD0103 - Lymphocytic Leukemia, Chronic | Phase 2 | Completed | Mirati Therapeutics Inc. | 21 | 2007-01-01 | 2015-07-01 |
| A Phase I/II Study of MGCD0103 (MG-0103) in Combination With Gemcitabine MGCD0103, Gemcitabine - Tumors | Phase 1 / Phase 2 | Completed | Mirati Therapeutics Inc. | 47 | 2006-09-01 | 2015-07-01 |
| MGCD0103 in Elderly Patients With Previously Untreated AML/High Risk MDS or Adults With Relapsed/Refractory Disease MGCD0103 - Myelogenous Leukemia, Acute, Myelodysplastic Syndromes | Phase 2 | Terminated | Mirati Therapeutics Inc. | 35 | 2006-09-01 | 2015-07-01 |
| Study of MGCD0103 (MG-0103) in Patients With Relapsed or Refractory Hodgkin's Lymphoma MGCD0103 - Hodgkin's Lymphoma | Phase 2 | Terminated | Mirati Therapeutics Inc. | 51 | 2006-08-01 | 2015-07-03 |
| Study of MGCD0103 Given Three Times Weekly in Patients With Relapsed and Refractory Lymphoma MGCD0103 - Lymphoma | Phase 2 | Completed | Mirati Therapeutics Inc. | 74 | 2006-08-01 | 2015-07-01 |
| A Phase I/II Study of MGCD0103 With Azacitidine in Patients With High-Risk Myelodysplastic Syndrome (MDS) or Acute Myelogenous Leukemia MGCD0103 - Myelodysplastic Syndrome, Acute Myelogenous Leukemia | Phase 1 / Phase 2 | Completed | Mirati Therapeutics Inc. | 66 | 2006-01-01 | 2015-07-01 |
| A Phase I Study of MGCD0103 Given Three-Times Weekly In Patients With Leukemia Or Myelodysplastic Syndromes MGCD0103 - Leukemia, Myelodysplastic Syndromes | Phase 1 | Completed | Mirati Therapeutics Inc. | 29 | 2005-02-01 | 2015-01-08 |
Showing 20 of 22. Sign in to see all of them.
Myelodysplastic Syndromes (6) · Recurrence (4) · Carcinoma, Non-Small-Cell Lung (3) · Hodgkin Disease (3) · Leukemia (3) · Leukemia, Myeloid, Acute (3) · Lung Neoplasms (2) · Lymphoma (2) · Lymphoma, Large B-Cell, Diffuse (2) · Lymphoma, Non-Hodgkin (2) · Neoplasm Metastasis (2) · Neoplasms (2) · Breast Neoplasms (1) · Bronchiolitis Obliterans Syndrome (1) · Carcinoma, Transitional Cell (1)
Mirati Therapeutics Inc. (16) · Memorial Sloan Kettering Cancer Center (3) · Jonsson Comprehensive Cancer Center (1) · Sarcoma Alliance for Research through Collaboration (1) · University Health Network, Toronto (1)
United States (21) · Canada (10) · United Kingdom (1)
Gregory Reid, MSc, MBA (12) · Alison Moskowitz, MD (1) · Andrew Zelenetz, MD, PhD (1) · Edwin Choy, MD, PhD (1) · Isan Chen, MD (1) · Kathryn Arbour, MD (1) · Lillian Siu, MD (1) · Noah C. Federman, MD (1) · Shreyas Patel, MD (1)